Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Aug 4:13:179.
doi: 10.1186/s12916-015-0427-z.

Ethnicity and prostate cancer: the way to solve the screening problem?

Leonard P Bokhorst  1 , Monique J Roobol  2
Affiliations
Comment

Ethnicity and prostate cancer: the way to solve the screening problem?

Leonard P Bokhorst et al. BMC Med. .

Abstract

In their analysis in BMC Medicine, Lloyd et al. provide individual patient lifetime risks of prostate cancer diagnosis and prostate cancer death stratified by ethnicity. This easy to understand information is helpful for men to decide whether to start prostate-specific antigen testing (i.e. screening). A higher lifetime risk of prostate cancer death in some ethnic groups is not automatically a license to start screening. The potential benefit in the form of reducing metastases and death should still be weighed against the potential risk of over diagnosis. In case of ethnicity, this harm-to-benefit ratio does not differ between groups. Stratifying men for screening based on ethnicity is therefore not optimal and will not solve the current screening problem. Other methods for risk-stratifying men have been proven to produce a more optimal harm-to-benefit ratio. Please see related article: http://www.biomedcentral.com/1741-7015/13/171.

PubMed Disclaimer

Comment on

References

    1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027–35. doi: 10.1016/S0140-6736(14)60525-0. - DOI - PMC - PubMed
    1. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125–32. doi: 10.1093/jnci/djr500. - DOI - PMC - PubMed
    1. European Randomized study of Screening for Prostate Cancer. www.erspc.org. Last accessed at July 23, 2015
    1. Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 2012;367:595–605. doi: 10.1056/NEJMoa1201637. - DOI - PMC - PubMed
    1. Schroder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Eur Urol. 2012;62:745–52. doi: 10.1016/j.eururo.2012.05.068. - DOI - PubMed